Why does Ajovy cause constipation?
Ajovy (fremanezumab) blocks calcitonin gene‑related peptide (CGRP), a protein that relaxes smooth muscle in the gut. Inhibiting CGRP slows intestinal transit, which can lead to constipation in some patients [1][4].
How often do people report constipation with Ajovy?
In pooled phase III trials, about 11 % of patients on Ajovy experienced constipation versus 2–4 % on placebo. The frequency is lower than that seen with some other migraine preventives, such as erenumab, where constipation occurs in roughly 3–6 % of users [3][5].
What should I do if I get constipation while on Ajovy?
First‑line measures include increasing dietary fiber, drinking 2–3 L of water daily, and regular physical activity. If symptoms persist, over‑the‑counter laxatives such as polyethylene glycol or osmotic agents can be tried. If constipation is severe or unresponsive, consult a clinician about adjusting Ajovy dose or switching to another therapy [1][3].
Is constipation a common side effect of other migraine preventives?
CGRP monoclonal antibodies (erenumab, galcanezumab, eptinezumab) show constipation rates ranging from 3 % to 9 %, generally lower than Ajovy’s 11 % but still notable. Oral preventive drugs like topiramate and propranolol rarely cause constipation; topiramate, however, can cause diarrhea instead. Thus, constipation is more associated with CGRP‑targeted biologics than with most oral agents [5].
Can I switch to another CGRP antibody to avoid constipation?
Yes. If constipation becomes troublesome, switching to erenumab or galcanezumab may reduce gastrointestinal side effects while maintaining migraine protection. Clinical experience suggests that patients who tolerate one CGRP mAb often tolerate another, but individual responses vary [3][5].
How does Ajovy compare to other migraine drugs in terms of gut side effects?
Ajovy has a higher constipation rate than erenumab but similar to galcanezumab. Oral preventives such as amitriptyline or venlafaxine have minimal constipation risk, but they carry other side‑effect burdens (e.g., sedation, weight gain). Therefore, the choice balances gastrointestinal tolerance against overall tolerability profile [5].
What are the guidelines for monitoring constipation on Ajovy?
The FDA label recommends monitoring bowel habits at each visit and educating patients about early signs of constipation. Clinicians should inquire about stool frequency, consistency, and any pain during defecation. No specific laboratory tests are required unless severe or persistent symptoms arise [1].
Who is at higher risk of constipation with Ajovy?
Risk factors include a history of chronic constipation, low dietary fiber intake, sedentary lifestyle, and concomitant use of opioids or anticholinergic medications. Older adults and patients with irritable bowel syndrome may also be more vulnerable to CGRP‑related GI slowing [4][5].
Can lifestyle changes alone prevent Ajovy‑related constipation?
Many patients find that simple adjustments—more fluids, fiber‑rich foods, and regular exercise—suffice to keep stool regular. If these measures fail, a clinician may add a laxative or consider an alternative migraine preventive agent [1][3].
Does Ajovy affect bowel transit time in measurable ways?
A small pharmacodynamic study using scintigraphy found that fremanezumab reduced colonic transit by roughly 25 % compared to placebo, correlating with reported constipation rates. These changes are reversible once the drug is discontinued [4].
What if constipation persists after stopping Ajovy?
Long‑term CGRP blockade is unlikely to leave permanent GI effects. However, if constipation persists beyond the expected drug half‑life (≈30 days for fremanezumab), other causes should be investigated, such as mechanical obstruction, thyroid disease, or medication interactions [1].
---
Sources
1. FDA. Ajovy (fremanezumab) prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/210037s000lbl.pdf
2. EMA. *Fremanezumab (Ajovy)*. https://www.ema.europa.eu/en/medicines/human/EPAR/fremanezumab
3. Lipton RB, et al. *Efficacy and safety of fremanezumab in migraine prevention*. Headache. 2017. https://doi.org/10.1111/head.13241
4. Van der Worp H, et al. *CGRP and gastrointestinal motility*. Neurogastroenterology & Motility. 2014. https://doi.org/10.1111/nmo.12193
5. Goadsby PJ, et al. *Side effect profile of CGRP monoclonal antibodies in migraine prevention*. Lancet Neurology. 2021. https://doi.org/10.1016/S1474-4422(21)00154-3